President Trump’s administration has reclassified medical marijuana as a less dangerous drug, moving it from a Schedule I to a Schedule III controlled substance. This change, signed by the acting attorney general, marks a step toward broader federal acceptance and could boost research and profitability in the marijuana industry. However, marijuana remains illegal under federal law, and recreational use is still classified as a Schedule I drug. The reclassification allows businesses selling medical marijuana to claim tax deductions, potentially saving millions, but creates complications for those selling both medical and recreational cannabis. The Justice Department has suggested that tax benefits be applied retroactively, but this remains unclear.
QUESTION: How might the reclassification of medical marijuana impact the future of drug policy in the United States?
What to know about a federal order reclassifying medical marijuana as a less dangerous drug
